Brands Cannabis Medical Science

Cannabis Inhalers: The Next Big Thing For Asthma And Cancer Pain Relief?

To meet and fulfill the demands of people who need immediate relief but cannot or choose not to combust cannabis, Israeli scientists have created cannabis inhalers.

Asthma, lung diseases, and various respiratory issues are several reasons why people opt for cannabis consumption methods other than smoking. Although cannabis is consumed by millions of people, certain delivery methods aren’t particularly suitable because of one’s physical health. Fortunately, though, individuals can consume cannabis orally and sublingually, apply topical products on their skin, and even use transdermal patches. Inhalation via vaping is another option, which doesn’t have the same health ramifications as combustion does.

To meet and fulfill the demands of people who need immediate relief but cannot or choose not to combust cannabis, Israeli scientists have created cannabis inhalers. They’re intended to alleviate pain caused by cancer and to deliver medicinal benefits to individuals with respiratory issues like asthma. How do these cannabis inhalers work exactly though, and when will they be available to the public?

Collaboration Between Panaxia Pharmaceuticals & Rafa Pharmaceuticals

Recently, Israeli scientists have focused their efforts on creating the most effective and beneficial cannabis inhaler possible with the intent to help people with not only acute and chronic cancer-causing pain but also those with respiratory problems. Even though consuming cannabis through an inhaler is a new way to use the herb, this method is still being tested to ensure that all kinks will be resolved before the public has access to this product.

To Read The Rest Of This Article By Nicole Skrobinon Benzinga / The Fresh Toast

Published: March 20, 2020

SHARE
RELATED POSTS
Best Of: Art, Cannabis, Dry Cleaners, Florists
An Interview with Rebel Founder Bryan Gerber
Punch Edibles looking to operate but stuck in limbo as it awaits license

Leave Your Reply

*